

SB590885

B-Raf kinase (BRAF) inhibitor

Catalog #100-1656


5 mg

Product Description

SB590885 is a potent inhibitor of serine/threonine protein kinase B-Raf (BRAF; K_d = 300 pM), a key component in the extracellular signalregulated kinase (ERK; a group of MAP kinases) pathway (Takle et al.). Mutations in the B-Raf regulatory domain result in increased kinase activity, associated with maintaining tumorigenicity of melanoma and other cancers. SB590885 selectively inhibits B-Raf kinase activity by binding competitively to the ATP-binding domain of B-Raf (King et al.; Roskoski).

Alternative Names:	Not applicable
CAS Number:	405554-55-4
Chemical Formula:	C ₂₇ H ₂₇ N ₅ O ₂
Molecular Weight:	453.5 g/mol
Purity:	≥ 98%
Chemical Name:	5-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-(4-pyridinyl)-1H-imidazol-4-yl]-2,3-dihydro-1H-inden-1- one oxime
Channel and a second	

Structure:



Properties	
Product Format:	An off-white powder
Stability and Storage:	Product stable at -20°C as supplied. As a precaution, STEMCELL recommends storing all small molecules away from direct light. For long-term storage, store with a desiccant. Stable as supplied for 12 months from date of receipt.
Preparation:	• DMSO \leq 30 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 1 mg in 221 µL of DMSO. If not fully dissolved, warm the 10 mM stock solution in a 37°C water bath or incubator with periodic mixing until the solution is clear.
	Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported; however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.
	Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

CANCER RESEARCH

• Disrupts endolysosomal pathway resulting in accumulation of acidic vacuole-like vesicles and sensitizing human melanoma cell lines to endoplasmic reticulum stress (Palušová et al.).

• Inhibits ERK phosphorylation, cell proliferation, anchorage-independent growth of human melanoma cell lines, and reduces tumor growth in a mouse xenograft model (King et al.).

DISEASE MODELING

• Induces hypertrophy in rat cardiomyocytes and promotes cardiac hypertrophy in vivo in a mouse model (Clerk et al.).

References

Clerk A et al. (2022) Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo. Biochem J 479(3): 401–24.

King AJ et al. (2006) Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 66(23): 11100–5.

Palušová V et al. (2020) Dual targeting of BRAF and mTOR signaling in melanoma cells with pyridinyl imidazole compounds. Cancers 12(6): 1–24. Roskoski R. (2010) RAF protein-serine/threonine kinases: Structure and regulation. Biochem Biophys Res Commun 399(3): 313–7. Takle AK et al. (2006) The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 16(2): 378–81.

Related Products

For a complete list of small molecules available from STEMCELL Technologies, visit www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2024 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.